{"entity":{"id":"prosight-mced","kind":"trial","name":"ProSight (Weihe five-cancer test in a screening population)","aka":["ProSight"],"tldr":"A Chinese study that gave about 2,500 people without symptoms a blood test for lung, bowel, liver, stomach and gullet cancer.","summary":"ProSight (NCT06790355) is a single-arm interventional study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Fudan University. It evaluated the feasibility of a blood test designed to detect lung, colorectal, liver, gastric and oesophageal cancer, which gives a binary result and predicts the signal origin.\n\nThe registry record, read on 29 October 2026, gives its status as completed, with 2,527 participants enrolled, a start on 1 March 2025 and primary completion on 31 August 2026.","status":"completed","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT06790355","url":"https://clinicaltrials.gov/study/NCT06790355"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06790355","phase":"not-applicable","setting":"Adults without symptoms at four Chinese centres, given a blood test for five cancers alongside usual screening with diagnostic work-up of positives","sponsor":"Shanghai Weihe Medical Laboratory Co., Ltd. with Fudan University","started":"2025-03-01","startedType":"actual","enrolled":2527,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/prosight-mced/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}